Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical phenotypes of castration-resistant prostate cancer.

Clinical advances in hematology & oncology : H&O - 1 Nov 2013

Zhang Tian, Armstrong Andrew J

Abstract excerpt

Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that no longer responds to androgen deprivation therapy. At the genome level, CRPC is a heterogeneous disease that is marked by a range of genetic and epigenetic lesions. These lesions differ from patient to patient, but ha...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgen Antagonists
Share to Phenotype
Share to Prostatic Neoplasms, Castration-Resistant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24896544

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24896544-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical phenotypes of castration-resistant prostate cancer.PMID 24896544Read ↗

Molecular Subtypes of Prostate Cancer.Semantic proximity Read ↗

Development and prevalence of castration-resistant prostate cancer subtypesSemantic proximity Read ↗

Identification and Validation of the Prognostic Impact of Metastatic Prostate Cancer Phenotypes.Semantic proximity Read ↗

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.Semantic proximity Read ↗

De Novo Metastatic Prostate Cancer: Are We Moving towards a Personalized Treatment?Semantic proximity Read ↗

Clinical variability and molecular heterogeneity in prostate cancerSemantic proximity Read ↗

De Novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment?Semantic proximity Read ↗

The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approachesSemantic proximity Read ↗

Neuroendocrine Prostate Cancer: Subtypes, Biology, and Clinical OutcomesSemantic proximity Read ↗

Molecular landscape for risk prediction and personalized therapeutics of castration-resistant prostate cancer: at a glanceSemantic proximity Read ↗

Molecular pathogenesis and progression of prostate cancer.Semantic proximity Read ↗

Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approachesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.